Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

This publication has 32 references indexed in Scilit:

• Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
  JNCI Journal of the National Cancer Institute, 2008
• Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98
  Journal of Clinical Oncology, 2007
• Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
  British Journal of Cancer, 2007
• Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
  The Lancet, 2007
• Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole
  British Journal of Cancer, 2006
• Ki‐67 expression in breast carcinoma
  Cancer, 2003
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002
• The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices fornode-negative breast cancer
  European Journal of Surgical Oncology, 1999
• The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1996
• Nonparametric Estimation from Incomplete Observations
  Journal of the American Statistical Association, 1958